
indie Semiconductor Reports First Quarter 2025 Results
ALISO VIEJO, Calif.--(BUSINESS WIRE)--indie Semiconductor, Inc. (Nasdaq: INDI), an automotive solutions innovator, today announced first quarter results for the period ended March 31, 2025. Q1 revenue was up 3.3 percent year-over-year to $54.1 million with Non-GAAP gross margin of 49.5 percent. On a GAAP basis, first quarter 2025 operating loss was $38.9 million compared to $49.6 million a year ago. Non-GAAP operating loss for the first quarter of 2025 was $15.1 million, versus $17.2 million during the same period last year. First quarter 2025 GAAP loss per share was $0.18, while Non-GAAP loss per share was $0.08.
'In Q1, indie delivered year-over-year growth despite persisting negative global macro-economic conditions and accelerated market uncertainty due to the dynamic tariff situation," said Donald McClymont, indie's co-founder and chief executive officer. 'In the context of this challenging market environment, our Q1 results demonstrate an enduring business resilience, with growth through 2025 and beyond underpinned by an innovative product portfolio, strong and growing design-win activity, and multiple anticipated product ramps for our class-leading ADAS solutions.'
Business Highlights
Secured iND880 vision processor in-cabin monitoring design-win with Valeo for a North American OEM
Awarded eMirror design-win for iND880 vision processor for Korean OEM targeting trucks and buses
Multiple design-wins in China for GW5 vision processor including Mercedes China for eMirror and BYD for in-cabin monitoring
Selected by Bosch for second high-volume in-cabin monitoring application for Toyota
iND87200 achieved full Qi wireless charging standards certification by three Tier 1 customers
High-performance laser solutions achieve multiple design-wins for industrial measurement applications
Surpassed 500 million cumulative chips shipped since company's inception
Operational Updates
As an acceleration of the previously communicated review of operational expenditure, we have initiated a series of measures expected to be completed by year-end, delivering annualized operational expense reductions of up to $40 million.
Q2 2025 Outlook
We provide guidance on a non-GAAP basis only because certain information necessary to reconcile such results and guidance to GAAP is difficult to estimate and dependent on future events outside of our control and, therefore, is not available without unreasonable efforts. Please refer to the header captioned 'Discussion Regarding the Use of Non-GAAP Financial Measures' in this release for a further discussion of our use of non-GAAP measures.
With the current market uncertainty continuing to impact the timing of anticipated production ramps in 2025, with current visibility, indie expects revenue between $50 and $53 million, or $51.5 million at the mid-point.
indie's Q1 2025 Conference Call
indie Semiconductor will host a conference call with analysts to discuss its first quarter 2025 results and business outlook today at 5:00 p.m. Eastern time. To listen to the conference call via the Internet, please go to the Financials tab on the Investors page of indie's website. To listen to the conference call via telephone, please call (877) 451-6152 (domestic) or (201) 389-0879 (international), Conference ID: 13752893.
A replay of the conference call will be available beginning at 9:00 p.m. Eastern time on May 12, 2025, until 11:59 p.m. Eastern time on May 26, 2025, under the Financials tab on the Investors page of indie's website, or by calling (844) 512-2921 (domestic) or (412) 317-6671 (international), Access ID: 13752893.
About indie
Headquartered in Aliso Viejo, CA, indie is empowering the automotive revolution with next generation semiconductors, photonics and software platforms. We focus on developing innovative, high-performance and energy-efficient technology for ADAS, in-cabin user experience and electrification applications. Our mixed-signal SoCs enable edge sensors spanning Radar, LiDAR, Ultrasound, and Computer Vision, while our embedded system control, power management and interfacing solutions transform the in-cabin experience and accelerate increasingly automated and electrified vehicles. As a global innovator, we are an approved vendor to Tier 1 partners and our solutions can be found in marquee automotive OEMs worldwide.
Please visit us at www.indie.inc to learn more.
Safe Harbor Statement
This communication contains 'forward-looking statements' (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended). Such statements can be identified by words such as 'will likely result,' 'expect,' 'anticipate,' 'estimate,' 'believe,' 'intend,' 'plan,' 'project,' 'outlook,' 'should,' 'could,' 'may' or words of similar meaning and include, but are not limited to, statements regarding our future business and financial performance and prospects, including statements regarding general global macro-economic conditions and market uncertainty due to the dynamic tariff situation, expectations regarding our growth, multiple product ramps through 2025 and path to profitability, expected timing, completion and impacts of operational expense reduction measures and other characterizations of future events or circumstances. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results included in such forward-looking statements. In addition to the factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on March 3, 2025 and in our other public reports filed with the SEC (including those identified under 'Risk Factors' therein), the following factors, among others, could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: macroeconomic conditions, including inflation, rising interest rates and volatility in the credit and financial markets, our reliance on contract manufacturing and outsourced supply chain and the availability of semiconductors and manufacturing capacity; competitive products and pricing pressures; our ability to win competitive bid selection processes and achieve additional design wins; the impact of recent acquisitions made and any other acquisitions we may make, including our ability to successfully integrate acquired businesses and risks that the anticipated benefits of any acquisitions may not be fully realized or take longer to realize than expected; our ability to develop, market and gain acceptance for new and enhanced products and expand into new technologies and markets; current and potential trade restrictions and trade tensions, including trade and tariff actions taken or proposed by the US government affecting the countries where we operate and political or economic instability in our target markets. All forward-looking statements in this press release are expressly qualified in their entirety by the foregoing cautionary statements.
Investors are cautioned not to place undue reliance on the forward-looking statements in this press release, which information set forth herein speaks only as of the date hereof. We do not undertake, and we expressly disclaim, any intention or obligation to update any forward-looking statements made in this announcement or in our other public filings, whether as a result of new information, future events or otherwise, except as required by law.
#indieSemi_Earnings
INDIE SEMICONDUCTOR, INC.
PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
(Unaudited)
March 31,
2025
December 31,
2024
Assets
Current assets:
Cash and cash equivalents
$
236,608
$
274,248
Restricted cash
10,297
10,300
Accounts receivable, net
62,880
52,005
Inventory, net
47,822
49,887
Prepaid expenses and other current assets
24,106
22,308
Total current assets
381,713
408,748
Property and equipment, net
34,868
34,281
Intangible assets, net
203,138
208,944
Goodwill
267,590
266,368
Operating lease right-of-use assets
15,310
16,107
Other assets and deposits
6,403
6,938
Total assets
$
909,022
$
941,386
Liabilities and stockholders' equity
Accounts payable
$
18,474
$
28,326
Accrued payroll liabilities
6,446
5,573
Contingent considerations
2,873
3,589
Accrued expenses and other current liabilities
26,754
29,297
Intangible asset contract liability
5,500
5,875
Current debt obligations
11,989
12,220
Total current liabilities
72,036
84,880
Long-term debt, net of current portion
367,037
369,097
Intangible asset contract liability, net of current portion
10,593
11,965
Deferred tax liabilities, non-current
11,750
11,660
Operating lease liability, non-current
13,555
14,278
Other long-term liabilities
2,318
4,111
Total liabilities
477,289
495,991
Commitments and contingencies
Stockholders' equity
Preferred stock
—
—
Class A common stock
19
19
Class V common stock
2
2
Additional paid-in capital
956,888
936,564
Accumulated deficit
(528,590
)
(494,044
)
Accumulated other comprehensive loss
(22,751
)
(24,655
)
indie's stockholders' equity
405,568
417,886
Noncontrolling interest
26,165
27,509
Total stockholders' equity
431,733
445,395
Total liabilities and stockholders' equity
$
909,022
$
941,386
Expand
INDIE SEMICONDUCTOR, INC.
(Unaudited)
Expand
GAAP refers to financial information presented in accordance with U.S. Generally Accepted Accounting Principles. This press release includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission. We believe that our presentation of non-GAAP financial measures provides useful supplementary information to investors. The presentation of non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results prepared in accordance with GAAP.
The reconciliations of our preliminary GAAP to non-GAAP measures are as follows (in thousands, except share and per share amounts):
Three Months Ended
March 31,
2025
2024
Computation of non-GAAP gross margin:
GAAP revenue
$
54,077
$
52,353
GAAP cost of goods sold
31,528
30,089
Acquisition-related expenses
(110
)
(110
)
Amortization of intangible assets
(3,839
)
(3,735
)
Inventory cost realignments
—
(145
)
Share-based compensation
(293
)
(100
)
Non-GAAP gross profit
$
26,791
$
26,354
Non-GAAP gross margin
49.5
%
50.3
%
Expand
Three Months Ended
March 31,
2025
2024
Computation of non-GAAP operating loss:
GAAP loss from operations
$
(38,933
)
$
(49,647
)
Acquisition-related and other non-recurring professional expenses
160
1,195
Amortization of intangible assets
5,970
5,771
Inventory cost realignments
—
145
Share-based compensation
17,743
25,384
Non-GAAP operating loss
$
(15,060
)
$
(17,152
)
Expand
March 31,
2025
2024
Computation of non-GAAP net loss:
Net loss
$
(37,171
)
$
(34,223
)
Acquisition-related and other non-recurring professional expenses
160
1,195
Amortization of intangible assets
5,970
5,771
Inventory cost realignments
—
145
Share-based compensation
17,743
25,384
Gain from change in fair value of contingent considerations and acquisition-related holdbacks
(4,803
)
(15,359
)
Other expense
736
247
Non-cash interest expense
657
250
Income tax (benefit) expense
56
(1,109
)
Non-GAAP net loss
$
(16,652
)
$
(17,699
)
Expand
Three Months Ended
March 31,
2025
2024
Computation of Non-GAAP EBITDA:
Net loss
$
(37,171
)
$
(34,223
)
Interest income
(2,267
)
(1,309
)
Interest expense
4,516
2,106
Gain from change in fair value of contingent considerations and acquisition-related holdbacks
(4,803
)
(15,359
)
Other expenses
736
247
Income tax (benefit) expense
56
(1,109
)
Depreciation and amortization
7,894
7,307
Stock-based compensation
17,743
25,384
Inventory cost realignments
—
145
Acquisition-related and other non-recurring professional expenses
160
1,195
Non-GAAP EBITDA
$
(13,136
)
$
(15,616
)
Expand
Discussion Regarding the Use of Non-GAAP Financial Measures
Our earnings release contains some or all of the following financial measures that have not been calculated in accordance with United States Generally Accepted Accounting Principles ('GAAP'): (i) non-GAAP gross profit and gross margin, (ii) non-GAAP operating loss, (iii) non-GAAP net loss, (iv) non-GAAP EBITDA, (v) non-GAAP share count, (vi) non-GAAP net loss and (vii) non-GAAP net loss per share. As set forth in the tables above, we derive such non-GAAP financial measures by excluding certain expenses and other items from the respective GAAP financial measure that is most directly comparable to each non-GAAP financial measure. Management may use these non-GAAP financial measures to, amongst other things, evaluate operating performance and compare it against past periods or against peer companies, make operating decisions, forecast for future periods and to determine payments under compensation programs. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods and competitors more difficult, obscure trends in ongoing operations or improve management's ability to forecast future periods.
We provide investors with non-GAAP gross profit and gross margin, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share because we believe it is important for investors to be able to closely monitor and understand changes in our ability to generate income from ongoing business operations. We believe these non-GAAP financial measures give investors an additional method to evaluate historical operating performance and identify trends, an additional means of evaluating period-over-period operating performance and a method to facilitate certain comparisons of our operating results to those of our peer companies. We further believe these non-GAAP financial measures allow investors to assess the overall financial performance of our ongoing operations by eliminating the impact of (i) acquisition-related and other non-recurring professional expenses (including acquisition-related or other non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) inventory cost realignments, (iv) gains or losses recognized in relation to changes in the fair value of warrants, contingent considerations issued by indie, acquisition-related holdbacks and unrealized gains or losses from currency hedging contracts, (v) non-cash interest expenses related to the amortization of debt discounts and issuance costs, (vi) share-based compensation, and (vii) income tax benefit (expenses). We believe that disclosing these non-GAAP financial measures contributes to enhanced financial reporting transparency and provides investors with added clarity about complex financial performance measures.
We do not report a GAAP measure of gross profit or gross margin because certain costs related to contract revenues are expensed as incurred and included in research and development expenses, and not in cost of sales, as it is not practicable for us to bifurcate these expenses. We derive and reconcile non-GAAP gross profit from the most relevant GAAP financial measures by subtracting GAAP cost of sales, adjusted for acquisition-related and other non-recurring professional expenses and share-based compensation, from GAAP revenue. We calculate non-GAAP operating loss by excluding from GAAP operating loss, any (i) acquisition-related and other non-recurring professional expenses (including acquisition-related or other non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) inventory cost realignments and (iv) share-based compensation. We calculate non-GAAP net loss by excluding from GAAP net income (loss), any (i) acquisition-related and other non-recurring professional expenses (including acquisition-related or non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) inventory cost realignments, (iv) gains or losses recognized in relation to changes in the fair value of warrants, contingent considerations issued by indie, acquisition-related holdbacks and unrealized gains or losses from currency hedging contracts, (v) non-cash interest expenses related to the amortization of debt discounts and issuance costs, (vi) share-based compensation, and (vii) income tax benefit (expenses). We calculate non-GAAP EBITDA by excluding from GAAP net income (loss), any (i) acquisition-related and other non-recurring professional expenses (including acquisition-related or non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) depreciation of fixed assets, (iv) inventory cost realignments, (v) gains or losses recognized in relation to changes in the fair value of warrants, contingent considerations issued by indie, acquisition-related holdbacks and unrealized gains or losses from currency hedging contracts, (vi) non-cash interest expenses related to the amortization of debt discounts and issuance costs, (vii) share-based compensation, and (viii) income tax benefit (expenses). We calculate non-GAAP share count by adding (i) weighted average Class A common stock, (ii) weighted average Class V common stock held by minority shareholders, which are exchangeable into Class A common stock, (iii) Escrow Shares and (iv) vested but unexercised options issued as part of the TeraXion acquisition. Non-GAAP net loss per share is calculated by dividing non-GAAP net loss by non-GAAP share count.
We exclude the items identified above from the respective non-GAAP financial measure referenced above for the reasons set forth with respect to each such excluded item below:
Acquisition-related and other non-recurring professional expenses - including such items as, when applicable, fair value charges incurred upon the sale of acquired inventory, accounting impact to the cost of goods sold due to one-time inventory costing realignment with a specific supplier, acquisition-related professional fees and legal expenses and other professional fees that are non-recurring in nature because they are not considered by management in making operating decisions and we believe that such expenses do not have a direct correlation to our future business operations and thereby including such charges do not necessarily reflect the performance of our ongoing operations for the period in which such charges or reversals are incurred.
Amortization expenses - related to the amortization expense for acquired intangible assets and certain license rights.
Depreciation expenses - related to the depreciation expenses for all property and equipment on hand.
Inventory cost realignments - related to the supplier allocation premiums introduced during COVID that is currently incorporated in our inventory cost but have since been eliminated going forward. The impact of this premium is deemed non-recurring and therefore not considered by management in its evaluation of the ongoing performance of the business.
Share-based compensation - related to the non-cash compensation expense associated with equity awards granted to our employees (including those granted in lieu of cash compensation) and employer tax related to employee stock transactions. These expenses are not considered by management in making operating decisions and such expenses do not have a direct correlation to our future business operations.
Restructuring costs - related to the one-time expenses the Company incurs to reorganize its operations, which is primarily related to workforce reduction, facilities and other purchase commitment charges.
Gain (loss) from change in fair values - because these adjustments (1) are not considered by management in making operating decisions, (2) are not directly controlled by management, (3) do not necessarily reflect the performance of our ongoing operations for the period in which such charges are recognized and (4) cannot make comparisons between peer company performance less reliable.
Non-cash interest expense - related to the amortization of debt discounts and issuance costs because (1) these expenses are not considered by management in making decision with respect to financing decisions, and (2) these generally reflect non-cash costs.
Income tax benefit (expense) - related to the estimated income tax benefit (expense) that does not result in a current period tax refunds (payments).
The non-GAAP financial measures presented should not be considered in isolation and are not an alternative for the respective GAAP financial measure that is most directly comparable to each such non-GAAP financial measure. Investors are cautioned against placing undue reliance on these non-GAAP financial measures and are urged to review and consider carefully the adjustments made by management to the most directly comparable GAAP financial measures to arrive at these non-GAAP financial measures. Non-GAAP financial measures may have limited value as analytical tools because they may exclude certain expenses that some investors consider important in evaluating our operating performance or ongoing business performance. Further, non-GAAP financial measures are likely to have limited value for purposes of drawing comparisons between companies as a result of different companies potentially calculating similarly titled non-GAAP financial measures in different ways because non-GAAP measures are not based on any comprehensive set of accounting rules or principles.
Non-GAAP EBITDA is calculated by removing non-recurring, irregular and one-time items that may distort EBITDA, to the current non-GAAP financial measures. We calculate non-GAAP EBITDA by excluding from GAAP net income (loss), any (i) acquisition-related and other non-recurring expenses (including acquisition-related or other non-recurring professional fees and legal expenses, deemed compensation expense and expenses recognized in relation to changes in contingent consideration obligations), (ii) amortization of acquisition-related intangibles and certain license rights, (iii) depreciation of property, plant and equipment, (iv) inventory cost realignments, (v) gains or losses recognized in relation to changes in the fair value of warrants, contingent considerations issued by indie, acquisition-related holdbacks and unrealized gains or losses from currency hedging contracts, (vi) non-cash interest expenses related to the amortization of debt discounts and issuance costs, (vii) share-based compensation, and (viii) income tax benefit (expenses).
To the extent our disclosures contain forward-looking estimates of non-GAAP financial measures, such as our forward-looking outlook for non-GAAP EBITDA, these measures are provided to investors on a prospective basis for the same reasons (set forth above) we provide them to investors on a historical basis. We are generally unable to provide a reconciliation of our forward-looking non-GAAP measures because certain information needed to make a reasonable forward-looking estimate of such non-GAAP measures are difficult to predict and estimate and is often dependent on future events that may be uncertain or outside of our control and, therefore, is not available without unreasonable efforts. Such events may include unanticipated changes in our GAAP effective tax rate, unanticipated one-time charges related to asset impairments (fixed assets, inventory, intangibles, or goodwill), unanticipated acquisition-related and other non-recurring professional expenses, unanticipated settlements, gains, losses and impairments and other unanticipated items not reflective of ongoing operations. Our forward-looking estimates of both GAAP and non-GAAP measures of our financial performance may differ materially from our actual results and should not be relied upon as statements of fact.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ('Gyre') (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A ('ETA') receptor antagonist, for the treatment of pulmonary arterial hypertension ('PAH').This milestone marks Gyre's entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China's National Rare Disease Catalog, underscoring its significance in public health. According to Frost & Sullivan, China's PAH market was valued at $370 million in 2023 and is projected to grow to $480 million by 2031.F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH Phase 1 trial is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The trial represents the latest expansion of Gyre's fibrosis-first strategy beyond the liver, leveraging a robust clinical development platform and commercial infrastructure in China.F230 joins Gyre's pipeline alongside lead candidate Hydronidone (F351), which met the primary endpoint in a pivotal Phase 3 trial for CHB-fibrosis. A New Drug Application ('NDA') submission to China's National Medical Products Administration ('NMPA') is planned for the third quarter of 2025, and a pre-IND meeting with the U.S. Food and Drug Administration is being planned for an expected Phase 2 trial in metabolic dysfunction-associated steatohepatitis ('MASH') Gyre TherapeuticsGyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre's strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People's Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning the expectations regarding Gyre's research and development efforts and timing of expected clinical trials, including an NDA submission to the NMPA for F351, the expected clinical benefits of F230 and expectations regarding interactions with regulators. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' 'plan' or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre's ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre's capital resources and its ability to raise additional capital. Additional risks and factors are identified under 'Risk Factors' in Gyre's Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC. Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by Contact:David ZhangGyre in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
19 minutes ago
- Business Wire
HCLTech Expands Partnership With The Standard to Accelerate AI-led Transformation and Deliver Digital-first Services at Scale
NEW YORK & NOIDA, India--(BUSINESS WIRE)-- HCLTech, a leading global technology company, announced an expansion of its partnership with Standard Insurance Company (The Standard), a leading provider of financial protection products and services for employers and individuals. This expanded partnership with The Standard will deliver AI-driven infrastructure and application services to boost efficiency, support rapid growth and enhance customer experience. This collaboration will also accelerate The Standard's shift to an IT products and services-based operating model, enabling greater agility, customer value and progress toward the company's long-term digital transformation goals. HCLTech's GenAI-led service transformation platform, AI Force, digital engineering and cloud services will support The Standard's focus on exceptional customer service in the delivery of workplace benefits. This transformation will be further driven by a newly formed Joint Innovation Council and Digital Experience Office, reinforcing The Standard's commitment to innovation and delivering scalable, user-centric experiences. 'The Standard's growth journey has accelerated in recent years through digital transformation and acquisitions, and HCLTech has proven to be the best partner to help us scale efficiently and seamlessly with its digital-first and customer-focused approach,' said Laxman Prakash, Chief Information Security Officer and Head of IT Infrastructure and Security Management Organization at The Standard. 'We look forward to the positive impact that this ongoing partnership will provide for our customers.' 'We are excited about this extended partnership with The Standard, showcasing our deep commitment to the insurance sector,' said Anubhav Mehrotra, Senior Vice President, Head of Insurance, North America, at HCLTech. 'This collaboration underscores HCLTech's investment in AI-led capabilities and innovative talent, which have been pivotal in guiding The Standard through its digital transformation journey.' About HCLTech HCLTech is a global technology company, home to more than 223,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud and AI, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, High Tech, Semiconductor, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending March 2025 totaled $13.8 billion. To learn how we can supercharge progress for you, visit About The Standard The Standard is a family of companies dedicated to helping customers achieve financial well-being and peace of mind. In business since 1906, we are a leading provider of financial protection products and services for employers and individuals. Our products include group and individual disability insurance, group life and accidental death and dismemberment insurance, group dental and group vision insurance, absence management and paid family leave services, retirement plans products and services and annuities for employers and individuals. For more information about The Standard, visit and follow us on LinkedIn and Instagram.
Yahoo
25 minutes ago
- Yahoo
Bermuda International Long Term Insurers and Reinsurers (BILTIR) Enlists Oliver Wyman to Analyse Systemic Risk in Region with New Report
HAMILTON, Bermuda, June 10, 2025--(BUSINESS WIRE)--Bermuda International Long Term Insurers and Reinsurers (BILTIR) today announced the release of a new report, titled Analysis of Systemic Risk in the Bermuda Long-Term Insurance Sector, published by Oliver Wyman through BILTIR's commissioning. Using Oliver Wyman's independent research and a variety of data sources, the report concludes that Bermuda's long-term (re)insurance sector does not meaningfully contribute to global systemic risk. "Amid questions about systemic risk within the Bermuda (re)insurance sector, BILTIR engaged experts at Oliver Wyman to conduct an independent examination of the industry and regulatory environment within our jurisdiction," said Suzanne Williams-Charles, CEO of BILTIR. "Bermuda's system is in place to manage risk and protect policyholders, and this report verifies that Bermuda's diligent regulatory framework is effectively limiting any potential for systemic risk." The report evaluated three hypothetical scenarios frequently cited by regulators to question whether activities in the (re)insurance sector could trigger systemic risk. Specifically, Oliver Wyman analysed: Credit crisis triggering mass reinsurance capture Confidence shock triggering a mass lapse and sale of assets Withdrawal of insurer private credit demand The report concludes that safeguards are in place to limit regulatory risk, including regulatory requirements and market practices. Additionally, it finds that the inherent long-term nature of insurance liabilities effectively limits the potential consequences of any stress on the broader financial system. The report also provides recommendations to enhance stakeholders' abilities to analyse and evaluate the potential risks within Bermuda. These recommendations include increased public transparency on transactions, ongoing regulatory oversight, and risk-based understanding of asset and liability portfolios. Oliver Wyman maintained strict editorial control over the paper and developed its own conclusions from its analysis. Find the full report here. About BILTIRBermuda International Long Term Insurers and Reinsurers (BILTIR) represents the long-term insurers and reinsurers in Bermuda. Backed by Bermuda's over 40-year history of providing insurance solutions and at the forefront of the evolving long-term insurance industry, BILTIR represents the policy interests and drives advocacy for the market and its members. BILTIR membership is comprised of more than 70 annuity, life insurance, and reinsurance businesses and servicing companies on the island. To learn more, visit View source version on Contacts Ellie Kuhen330-697-1161ekuhen@ Sign in to access your portfolio